Table 1.

Experimental parameters

		Groups
Parameter	ANOVA	SDC	R2C	R2 LSp	R2 Sp
n		6	5	5	5
Age, wk	0.041	8.7 ± 0.3	8.2 ± 0.2	8.8 ± 0.4	9 ± 0.3
SBP, mmHg
Initial	<0.001	126 ± 4	145 ± 2*	154 ± 6*	150 ± 2*
Final	<0.001	140 ± 4	190 ± 3*	199 ± 7*	163 ± 7*†
Body weight, g
Initial	ND	103 ± 19	109 ± 2	138 ± 13	123 ± 4
Final	ND	256 ± 10	255 ± 7	267 ± 11	263 ± 6
HOMA-IR	ND	0.06 ± 0.02	0.15 ± 0.06	0.08 ± 0.01	0.02 ± 0.0

Values are means ± SE; n, sample size. Rats were divided into the following groups: Sprague-Dawley control (SDC), transgenic (mRen2)27 (R2) control (R2C), R2 rats treated with low-dose spironolactone (R2 LSp), and R2 rats treated with conventional-dose spironolactone (R2 Sp). Systolic blood pressure (SBP) and body weight were measured immediately before treatment (initial) and at the end of the treatment period (final). ND indicates that no differences were observed by ANOVA.

^*P < 0.05 vs. the SDC group;

^†P < 0.05 vs. the R2 LSp group.